SMTL ID : 4fob.1

Crystal structure of human anaplastic lymphoma kinase in complex with acyliminobenzimidazole inhibitor 1

Coordinates

PDB Format

Method

X-RAY DIFFRACTION 1.90 Å

Oligo State

monomer

Ligands

1 x 0US: N-{1-[cis-4-(hydroxymethyl)cyclohexyl]-5-(piperidin-1-ylmethyl)-1H-benzimidazol-2-yl}-3-(prop-2-en-1-ylsulfamoyl)benzamide(Non-covalent)

0US.1: 18 residues within 4Å: Chain A: L.65, G.66, H.67, G.68, V.73, A.91, K.93, L.139, E.140, L.141, M.142, A.143, G.144, G.145, R.196, N.197, L.199, G.212 7 PLIP interactions: 7 interactions with chain A Hydrophobic interactions: A:V.73, A:A.91, A:L.139, A:L.139, A:L.199 Hydrogen bonds: A:M.142, A:G.212

Links

RCSB   PDBe   PDBe-KB   PDBj   PDBsum   CATH   PLIP

Citation

Lewis, R.T. et al., The Discovery and Optimization of a Novel Class of Potent, Selective, and Orally Bioavailable Anaplastic Lymphoma Kinase (ALK) Inhibitors with Potential Utility for the Treatment of Cancer. J.Med.Chem. (2012)

Release Date

2012-07-11

Peptides

ALK tyrosine kinase receptor: A

SMTL:PDB

SMTL Chain Id:
PDB Chain Id:

A
A

ALK tyrosine kinase receptor

Related Entries With Identical Sequence